1
|
Soputro NA, Gracias DN, Dias BH, Nzenza T, O'Connell H, Sethi K. Utility of urinary biomarkers in primary haematuria: Systematic review and meta-analysis. BJUI COMPASS 2022; 3:334-343. [PMID: 35950042 PMCID: PMC9349596 DOI: 10.1002/bco2.147] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2022] [Revised: 03/01/2022] [Accepted: 03/14/2022] [Indexed: 01/15/2023] Open
Abstract
Objectives To evaluate the diagnostic performance of FDA-approved urinary biomarkers in the evaluation of primary haematuria for investigation of bladder cancer. Methods The scientific databases MEDLINE, EMBASE, Pubmed and Web of Science were searched to collect studies. Studies that evaluated the diagnostic performance of FDA-approved urinary biomarkers in investigating patients with primary haematuria without a prior history of bladder cancer were included. Quality of studies was assessed using the JBI Criteria. Bivariate mixed-effects regression model was used to calculate pooled sensitivities and specificities for each biomarker. Results Eighteen studies were included in the analysis. The biomarkers assessed in these studies were CxBladder, AssureMDx, Bladder Tumour Antigen (BTA), NMP22, UroVysion and Immunocyt/uCyt+. Several biomarkers, such as AssureMDx, CxBladder and Immunocyt, were shown to have better diagnostic performance based on their sensitivity, specificity and diagnostic odds ratio, as well as positive and negative likelihood ratios. Across the six biomarkers, sensitivity ranged from 0.659 to 0.973, and the specificity ranged between 0.577 and 0.833. Conclusion Despite certain biomarkers demonstrated better performance, current diagnostic abilities of the FDA-approved biomarkers remain insufficient for their general application as a rule out test for bladder cancer diagnosis and as a triage test for cystoscopy in patients with primary haematuria. High-quality prospective studies are required to further analyse this and also analyse the correct scenario in which urinary biomarkers may be best utilised.
Collapse
Affiliation(s)
| | - Dylan Neil Gracias
- Melbourne Medical School, Faculty of Medicine, Dentistry, and Health SciencesUniversity of MelbourneParkvilleVictoria3010Australia
| | - Brendan Hermenigildo Dias
- Department of UrologyWestern HealthFootscrayVictoria3011Australia
- Department of SurgeryThe University of MelbourneParkvilleVictoria3010Australia
| | - Tatenda Nzenza
- Department of UrologyWestern HealthFootscrayVictoria3011Australia
| | - Helen O'Connell
- Department of UrologyWestern HealthFootscrayVictoria3011Australia
- Department of SurgeryThe University of MelbourneParkvilleVictoria3010Australia
| | - Kapil Sethi
- Department of UrologyWestern HealthFootscrayVictoria3011Australia
- Department of SurgeryThe University of MelbourneParkvilleVictoria3010Australia
| |
Collapse
|
2
|
Noninvasive diagnostic imaging using machine-learning analysis of nanoresolution images of cell surfaces: Detection of bladder cancer. Proc Natl Acad Sci U S A 2018; 115:12920-12925. [PMID: 30509988 DOI: 10.1073/pnas.1816459115] [Citation(s) in RCA: 68] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
We report an approach in diagnostic imaging based on nanoscale-resolution scanning of surfaces of cells collected from body fluids using a recent modality of atomic force microscopy (AFM), subresonance tapping, and machine-leaning analysis. The surface parameters, which are typically used in engineering to describe surfaces, are used to classify cells. The method is applied to the detection of bladder cancer, which is one of the most common human malignancies and the most expensive cancer to treat. The frequent visual examinations of bladder (cytoscopy) required for follow-up are not only uncomfortable for the patient but a serious cost for the health care system. Our method addresses an unmet need in noninvasive and accurate detection of bladder cancer, which may eliminate unnecessary and expensive cystoscopies. The method, which evaluates cells collected from urine, shows 94% diagnostic accuracy when examining five cells per patient's urine sample. It is a statistically significant improvement (P < 0.05) in diagnostic accuracy compared with the currently used clinical standard, cystoscopy, as verified on 43 control and 25 bladder cancer patients.
Collapse
|
3
|
Pallaoro A, Mirsafavi RY, Culp WT, Braun GB, Meinhart CD, Moskovits M. Screening for canine transitional cell carcinoma (TCC) by SERS-based quantitative urine cytology. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2018; 14:1279-1287. [DOI: 10.1016/j.nano.2018.03.001] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/12/2017] [Revised: 02/17/2018] [Accepted: 03/11/2018] [Indexed: 12/25/2022]
|
4
|
Kumar N, Talwar R, Nandy P. Efficacy of voided urinary cytology and ultrasonography compared to cystoscopy in the detection of urinary bladder cancer. AFRICAN JOURNAL OF UROLOGY 2017. [DOI: 10.1016/j.afju.2017.01.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
5
|
Palmer S, Litvinova K, Dunaev A, Yubo J, McGloin D, Nabi G. Optical redox ratio and endogenous porphyrins in the detection of urinary bladder cancer: A patient biopsy analysis. JOURNAL OF BIOPHOTONICS 2017; 10:1062-1073. [PMID: 27714989 DOI: 10.1002/jbio.201600162] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/30/2016] [Revised: 08/10/2016] [Accepted: 08/21/2016] [Indexed: 06/06/2023]
Abstract
Bladder cancer is among the most common cancers in the UK and conventional detection techniques suffer from low sensitivity, low specificity, or both. Recent attempts to address the disparity have led to progress in the field of autofluorescence as a means to diagnose the disease with high efficiency, however there is still a lot not known about autofluorescence profiles in the disease. The multi-functional diagnostic system "LAKK-M" was used to assess autofluorescence profiles of healthy and cancerous bladder tissue to identify novel biomarkers of the disease. Statistically significant differences were observed in the optical redox ratio (a measure of tissue metabolic activity), the amplitude of endogenous porphyrins and the NADH/porphyrin ratio between tissue types. These findings could advance understanding of bladder cancer and aid in the development of new techniques for detection and surveillance.
Collapse
Affiliation(s)
- Scott Palmer
- Division of Imaging and Technology, University of Dundee, Ninewells Hospital and Medical School, James Arrott Drive, Dundee, UK DD1 9SY
| | - Karina Litvinova
- Optoelectronics and Biomedical Photonics Group, Aston Institute of Photonic Technologies, Aston University, Aston Triangle, Birmingham, UK B4 7ET
| | - Andrey Dunaev
- Biomedical Photonics Instrumentation Group, Scientific-Educational Centre of "Biomedical Engineering", Orel State University, Orel, Russia, 302020
| | - Ji Yubo
- Division of Imaging and Technology, University of Dundee, Ninewells Hospital and Medical School, James Arrott Drive, Dundee, UK DD1 9SY
| | - David McGloin
- SUPA, School of Science and Engineering, Ewing Building, University of Dundee, Nethergate, Dundee, UK DD1 4HN
| | - Ghulam Nabi
- Division of Imaging and Technology, University of Dundee, Ninewells Hospital and Medical School, James Arrott Drive, Dundee, UK DD1 9SY
| |
Collapse
|
6
|
Vu Van D, Heberling U, Wirth MP, Fuessel S. Validation of the diagnostic utility of urinary midkine for the detection of bladder cancer. Oncol Lett 2016; 12:3143-3152. [PMID: 27899974 PMCID: PMC5103912 DOI: 10.3892/ol.2016.5040] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2016] [Accepted: 07/12/2016] [Indexed: 01/06/2023] Open
Abstract
As it has been demonstrated previously that midkine (also known as neurite growth-promoting factor 2) protein levels in urine of bladder cancer (BCa) patients are increased compared to healthy controls, the present study validated the diagnostic utility of midkine in an independent patient cohort and compared the observed values with voided urine cytology (VUC), which is the current reference standard for non-invasive diagnosis of BCa. Voided urine samples were prospectively collected from 92 BCa patients and 70 control subjects. Protein levels of midkine were assessed using a commercially available enzyme-linked immunosorbent assay and normalized to urinary creatinine. The diagnostic performance of urinary midkine was evaluated by receiver operating characteristic curves. The best combinations of sensitivities and specificities were determined by Youden's Index. Midkine concentrations were significantly elevated in urine samples from BCa patients compared to controls (P<0.001; Mann-Whitney U Test). The level of midkine was associated with disease progression, with the highest concentrations in urine specimens of patients with pT1 and ≥pT2a, as well as high-grade tumors (P<0.001; Mann-Whitney U test). Sensitivities of urinary midkine and VUC were 69.7 and 87.6%, respectively. The corresponding specificities for midkine and VUC were 77.9 and 87.7%, respectively. The combined use of VUC and midkine improved the sensitivity to 93.3%, but reduced the specificity to 66.2%. Despite its reduced discriminatory power for low-grade and low-stage BCa, urinary midkine can be utilized for the identification of high-grade pT1 and ≥pT2a tumors. This means that midkine may potentially be suitable for the identification of patients with high risk BCa.
Collapse
Affiliation(s)
- Dana Vu Van
- Department of Urology, Technische Universität Dresden, D-01307 Dresden, Germany
| | - Ulrike Heberling
- Department of Urology, Technische Universität Dresden, D-01307 Dresden, Germany
| | - Manfred P Wirth
- Department of Urology, Technische Universität Dresden, D-01307 Dresden, Germany
| | - Susanne Fuessel
- Department of Urology, Technische Universität Dresden, D-01307 Dresden, Germany
| |
Collapse
|
7
|
He H, Han C, Hao L, Zang G. ImmunoCyt test compared to cytology in the diagnosis of bladder cancer: A meta-analysis. Oncol Lett 2016; 12:83-88. [PMID: 27347104 PMCID: PMC4906922 DOI: 10.3892/ol.2016.4556] [Citation(s) in RCA: 43] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2016] [Accepted: 05/12/2016] [Indexed: 11/05/2022] Open
Abstract
The aim of the present study was to evaluate the diagnostic value of the ImmunoCyt test compared with urine cytology in detecting bladder cancer. A systematic literature search was performed to locate all publications reporting on the diagnostic accuracy of the ImmunoCyt test for bladder cancer. Data were extracted from 2×2 tables or calculated from reported accuracy data. Collected data were meta-analyzed for sensitivity, specificity, positive likelihood ratio (LR), negative LR, diagnostic odds ratio (DOR), and summary receiver operator characteristic (sROC) curve analysis. We applied the Meta-DiSc 1.4 and STATA 13.0 software to the meta-analysis. Seven separate studies consisting of 1,602 patients with bladder cancer were considered in the meta-analysis. We found that the ImmunoCyt test had a higher sensitivity than the urine cytology test [0.725, 95% confidence interval (CI) 0.683-0.765 vs. 0.566, 95% CI, 0.521-0.611], but the specificity, positive LR, negative LR, DOR, area under the curve (AUC) and Q index of the ImmunoCyt test were lower compared with the urine cytology test. In addition, the pooled sensitivity, specificity, positive LR, negative LR, DOR, AUC, and Q index of the combined method (combination of ImmunoCyt and cytology) were 0.833, 0.644, 2.804, 0.228, 13.50, 0.8554 and 0.7863, respectively. The results of the Eggers test showed no publication bias (P>0.05). In conclusion, specificity, positive LR, negative LR, DOR, the AUC, and the Q index of the urine cytology test may be superior to the ImmunoCyt test, but the ImmunoCyt test has greater sensitivity than the urine cytology test. Use of ImmunoCyt and cytology in combination has the potential to improve the sensitivity and promises to be an alternative in the detection of bladder cancer.
Collapse
Affiliation(s)
- Houguang He
- The Affiliated Xuzhou Hospital of Medical College of Southeast University, Xuzhou Central Hospital, Xuzhou, Jiangsu 221009, P.R. China
| | - Conghui Han
- The Affiliated Xuzhou Hospital of Medical College of Southeast University, Xuzhou Central Hospital, Xuzhou, Jiangsu 221009, P.R. China
| | - Lin Hao
- The Affiliated Xuzhou Hospital of Medical College of Southeast University, Xuzhou Central Hospital, Xuzhou, Jiangsu 221009, P.R. China
| | - Guanghui Zang
- The Affiliated Xuzhou Hospital of Medical College of Southeast University, Xuzhou Central Hospital, Xuzhou, Jiangsu 221009, P.R. China
| |
Collapse
|
8
|
van Kessel KEM, Van Neste L, Lurkin I, Zwarthoff EC, Van Criekinge W. Evaluation of an Epigenetic Profile for the Detection of Bladder Cancer in Patients with Hematuria. J Urol 2015; 195:601-7. [PMID: 26327355 DOI: 10.1016/j.juro.2015.08.085] [Citation(s) in RCA: 49] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/20/2015] [Indexed: 10/23/2022]
Abstract
PURPOSE Many patients enter the care cycle with gross or microscopic hematuria and undergo cystoscopy to rule out bladder cancer. Sensitivity of this invasive examination is limited, leaving many patients at risk for undetected cancer. To improve current clinical practice more sensitive and noninvasive screening methods should be applied. MATERIALS AND METHODS A total of 154 urine samples were collected from patients with hematuria, including 80 without and 74 with bladder cancer. DNA from cells in the urine was epigenetically profiled using 2 independent assays. Methylation specific polymerase chain reaction was performed on TWIST1. SNaPshot™ methylation analysis was done for different loci of OTX1 and ONECUT2. Additionally all samples were analyzed for mutation status of TERT (telomerase reverse transcriptase), PIK3CA, FGFR3 (fibroblast growth factor receptor 3), HRAS, KRAS and NRAS. RESULTS The combination of TWIST1, ONECUT2 (2 loci) and OTX1 resulted in the best overall performing panel. Logistic regression analysis on these methylation markers, mutation status of FGFR3, TERT and HRAS, and patient age resulted in an accurate model with 97% sensitivity, 83% specificity and an AUC of 0.93 (95% CI 0.88-0.98). Internal validation led to an optimism corrected AUC of 0.92. With an estimated bladder cancer prevalence of 5% to 10% in a hematuria cohort the assay resulted in a 99.6% to 99.9% negative predictive value. CONCLUSIONS Epigenetic profiling using TWIST1, ONECUT2 and OTX1 results in a high sensitivity and specificity. Accurate risk prediction might result in less extensive and invasive examination of patients at low risk, thereby reducing unnecessary patient burden and health care costs.
Collapse
Affiliation(s)
- Kim E M van Kessel
- Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Leander Van Neste
- Department of Pathology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands; MDxHealth, Inc., Irvine, California
| | - Irene Lurkin
- Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Ellen C Zwarthoff
- Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Wim Van Criekinge
- MDxHealth, Inc., Irvine, California; Laboratory of Bioinformatics and Computational Genomics, Ghent University, Ghent, Belgium.
| |
Collapse
|
9
|
Abstract
Bladder carcinoma is the most common malignancy of the urinary tract and cystoscopy with cytology is currently considered the gold standard for the detection and surveillance of primary tumors and for the follow-up of patients after transurethral resection. Even if cytology has a low sensitivity especially in low-grade bladder carcinomas, the high specificity and the inexpensive nature of the equipment required, justify performing it. The greatest value of cytology for patients with low-grade, nonmuscle-invasive bladder cancer (NMIBC) is the detection of those lesions that may progress to high-grade urothelial carcinoma.
Collapse
|
10
|
Clin B, Pairon JC. Medical follow-up for workers exposed to bladder carcinogens: the French evidence-based and pragmatic statement. BMC Public Health 2014; 14:1155. [PMID: 25377503 PMCID: PMC4230399 DOI: 10.1186/1471-2458-14-1155] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2014] [Accepted: 10/17/2014] [Indexed: 01/18/2023] Open
Abstract
BACKGROUND The aim of this work was to establish recommendations for the medical follow-up of workers currently or previously exposed to carcinogenic substances for the bladder. METHODS A critical synthesis of the literature was conducted. Sectors of activity where workers are or were exposed to carcinogenic substances for the bladder were listed and classified according to the level of bladder cancer risk. Performances of techniques available for the targeted screening of bladder cancer were analysed, including a simulation of results among high-risk populations in France. RESULTS The risk level for the professional group and the latency period between the start of exposure and the natural history of the disease were selected to define a targeted screening protocol. The NMP22BC test, exclusive haematuria testing, and combinations of urine cytology with, respectively, the NMP22BC test and haematuria test, generated an extremely high proportion of false positive results. CONCLUSION Urine cytology is the test that offers the best specificity. Although poor for all bladder cancer stages and grades combined, its sensitivity is better for high grades, which require early diagnosis since late-stage cancers are of very poor prognosis. These results suggest that urine cytology is currently the only technique suitable for proposal within the context of a first line targeted screening strategy for occupational bladder cancer. An algorithm summarising the recommended medical follow-up for workers currently or previously exposed to carcinogenic substances for the bladder is proposed, based on the level of risk of bladder cancer.
Collapse
Affiliation(s)
- Bénédicte Clin
- />Cancers and prevention, U1086 INSERM, Faculty of Medicine, Caen University Hospital, Caen, France
- />Service de Santé au Travail et Pathologie Professionnelle (Occupational Health Department), C.H.U. (University Hospital) Côte de Nacre, 14033 CAEN Cedex, France
| | - “RecoCancerProf” Working Group
- />Cancers and prevention, U1086 INSERM, Faculty of Medicine, Caen University Hospital, Caen, France
- />Service de Santé au Travail et Pathologie Professionnelle (Occupational Health Department), C.H.U. (University Hospital) Côte de Nacre, 14033 CAEN Cedex, France
- />INSERM, Unité 955, Université Paris-Est Créteil, 94000 Créteil, France
- />Centre Hospitalier Intercommunal de Créteil, Service de Pneumologie et de Pathologie Professionnelle, 94000 Créteil, France
| | - Jean-Claude Pairon
- />INSERM, Unité 955, Université Paris-Est Créteil, 94000 Créteil, France
- />Centre Hospitalier Intercommunal de Créteil, Service de Pneumologie et de Pathologie Professionnelle, 94000 Créteil, France
| |
Collapse
|
11
|
Abstract
Bladder cancer (BC) represents the fourth most common neoplasia in men and the ninth most common cancer in women, with a significant morbidity and mortality. Cystoscopy and voided urine cytology (involving the examination of cells in voided urine to detect the presence of cancerous cells) are currently the routine initial investigations in patients with hematuria or other symptoms suggestive of BC. Around 75-85% of the patients are diagnosed as having non-muscle-invasive bladder cancer (NMIBC). Despite the treatment, these patients have a probability of recurrence at 5 years ranging from 50 to 70% and of progression to muscle invasive disease of 10-15%. Patients with NMIBC must undergo life-long surveillance, consisting of serial cystoscopies, possibly urine cytology and ultrasonography. Cystoscopy is unsuitable for screening because of its invasiveness and costs; serial cystoscopies may cause discomfort and distress to patients. Furthermore, cystoscopy may be inconclusive, falsely positive or negative. Although urine cytology has a reasonable sensitivity for the detection of high-grade BC, it lacks sensitivity to detect low-grade tumors (sensitivity ranging from 4 to 31%). The overall sensitivity and specificity of urine cytology range from 7 to 100 and from 30 to 70%, respectively. There is a need for new urine biomarkers that may help in BC diagnosis and surveillance. A lot of urinary biomarkers with high sensitivity and/or specificity have been investigated. Although none of these markers have proven to be powerful enough to replace standard cystoscopy, some of them may represent accurate predictors of BC. A review of recent studies is presented.
Collapse
|
12
|
|
13
|
[How to apply follow-up in relation to risk group]. Urologia 2013; 80 Suppl 21:42-7. [PMID: 23559135 DOI: 10.5301/ru.2013.10864] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/20/2012] [Indexed: 11/20/2022]
Abstract
The term 'Non-muscle invasive bladder cancer' identifies a heterogeneous disease due to different natural history of its various appearances. T1 stage represents a non-predictable population, which might respond to non-operative treatment strategies or to the need of a more aggressive treatment, in order to avoid the progression to invasive, and possibly to metastatic stages. In the first year following transurethral resection of bladder (TURB), tumor recurrence is seen in up to 45% of the population; of this, 15% may progress to muscle invasive or metastatic disease, or both. In order to control the recurrence and progression and identify invasive tumors at the earliest possible stage, it is strongly necessary to define individual patient risk assessment follow-up. To obtain exact staging, besides a proper transurethral resection of bladder, a restaging transurethral resection of bladder should be performed in T1 patients. Data from literature support the immediate postoperative intravesical instillation of different chemotherapeutic agents in low-risk patients. Multifocal papillary lesions might require a more intensive adjuvant regimen, whereas intravesical immunotherapy using Bacillus Calmette-Guérin is recommended in patients at high risk of progression. Early cystectomy should be considered in patients with recurrent T1 tumors or refractory carcinoma in situ to avoid unfavorable tumor progression.
Collapse
|
14
|
Bolenz C, West AM, Ortiz N, Kabbani W, Lotan Y. Urinary cytology for the detection of urothelial carcinoma of the bladder—a flawed adjunct to cystoscopy? Urol Oncol 2013; 31:366-71. [DOI: 10.1016/j.urolonc.2011.01.017] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2010] [Revised: 01/26/2011] [Accepted: 01/27/2011] [Indexed: 11/26/2022]
|
15
|
Anastasiadis A, Cordeiro E, Bus MT, Alivizatos G, de la Rosette JJ, de Reijke TM. Follow-up procedures for non-muscle-invasive bladder cancer: an update. Expert Rev Anticancer Ther 2013; 12:1229-41. [PMID: 23098122 DOI: 10.1586/era.12.98] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Bladder carcinoma is the most common malignancy of the urinary tract. Approximately 75-85% of patients present with a disease that is confined to the mucosa (stage Ta, carcinoma in situ) or submucosa (stage T1). The stratification of patients to low-, intermediate- and high-risk groups represents the cornerstone for the indication of adjuvant and follow-up treatment. Owing to the high recurrence rate of bladder tumors, a surveillance protocol is recommended to all patients. Currently, the combination of cystoscopy, imaging and urinary cytology represent the follow-up. A systematic review of the recent English literature on follow-up procedures of non-muscle-invasive bladder cancer is performed. The authors review the existing follow-up procedures, with a focus on novel molecular-targeted approaches. At the present time, the additional use and utility of urine-based molecular markers in the follow-up of patients remains unclear and we have to rely on cystoscopic evaluation adapted to risk group classification.
Collapse
|
16
|
Casadio V, Calistri D, Tebaldi M, Bravaccini S, Gunelli R, Martorana G, Bertaccini A, Serra L, Scarpi E, Amadori D, Silvestrini R, Zoli W. Urine cell-free DNA integrity as a marker for early bladder cancer diagnosis: preliminary data. Urol Oncol 2012; 31:1744-50. [PMID: 23141783 DOI: 10.1016/j.urolonc.2012.07.013] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2012] [Revised: 07/27/2012] [Accepted: 07/30/2012] [Indexed: 01/05/2023]
Abstract
OBJECTIVES Urine cell-free (UCF) DNA has recently been proposed as a potential marker for early bladder cancer diagnosis. It is known that normal apoptotic cells produce highly fragmented DNA while cancer cells release longer DNA. Therefore, we verified the potential role of UCF DNA integrity in early bladder cancer diagnosis. MATERIALS AND METHODS UCF DNA was isolated from 51 bladder cancer patients, 46 symptomatic patients, and 32 healthy volunteers. To verify UCF DNA integrity, sequences longer than 250 bp, c-Myc, BCAS1, and HER2, were quantified by real time PCR. RESULTS At the best cutoff value of 0.1 ng/μl, UCF DNA integrity analysis showed a sensitivity of 0.73 (95% CI 0.61-0.85), and a specificity of 0.84 (95% CI 0.71-0.97) in healthy individuals and 0.83 (95% CI 0.72-0.94) in symptomatic patients. Receiver operating characteristic (ROC) curve analysis revealed an area under the curve of 0.834 (95% CI 0.739-0.930) for healthy individuals and 0.796 (95% CI 0.707-0.885) for symptomatic patients. CONCLUSIONS These preliminary data suggest that UCF DNA integrity is a potentially good marker for early noninvasive diagnosis of bladder cancer. Its diagnostic performance does not seem to vary significantly, even in an "at risk" population of symptomatic individuals.
Collapse
Affiliation(s)
- Valentina Casadio
- Biosciences Laboratory, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
van Tilborg AAG, Kompier LC, Lurkin I, Poort R, El Bouazzaoui S, van der Keur K, Zuiverloon T, Dyrskjot L, Orntoft TF, Roobol MJ, Zwarthoff EC. Selection of microsatellite markers for bladder cancer diagnosis without the need for corresponding blood. PLoS One 2012; 7:e43345. [PMID: 22927958 PMCID: PMC3425555 DOI: 10.1371/journal.pone.0043345] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2012] [Accepted: 07/19/2012] [Indexed: 01/02/2023] Open
Abstract
Microsatellite markers are used for loss-of-heterozygosity, allelic imbalance and clonality analyses in cancers. Usually, tumor DNA is compared to corresponding normal DNA. However, normal DNA is not always available and can display aberrant allele ratios due to copy number variations in the genome. Moreover, stutter peaks may complicate the analysis. To use microsatellite markers for diagnosis of recurrent bladder cancer, we aimed to select markers without stutter peaks and a constant ratio between alleles, thereby avoiding the need for a control DNA sample. We investigated 49 microsatellite markers with tri- and tetranucleotide repeats in regions commonly lost in bladder cancer. Based on analysis of 50 blood DNAs the 12 best performing markers were selected with few stutter peaks and a constant ratio between peaks heights. Per marker upper and lower cut off values for allele ratios were determined. LOH of the markers was observed in 59/104 tumor DNAs. We then determined the sensitivity of the marker panel for detection of recurrent bladder cancer by assaying 102 urine samples of these patients. Sensitivity was 63% when patients were stratified for LOH in their primary tumors. We demonstrate that up-front selection of microsatellite markers obliterates the need for a corresponding blood sample. For diagnosis of bladder cancer recurrences in urine this significantly reduces costs. Moreover, this approach facilitates retrospective analysis of archival tumor samples for allelic imbalance.
Collapse
Affiliation(s)
| | | | - Irene Lurkin
- Department of Pathology, Erasmus MC, Rotterdam, The Netherlands
| | - Ricardo Poort
- Department of Pathology, Erasmus MC, Rotterdam, The Netherlands
| | | | | | | | - Lars Dyrskjot
- Aarhus University Hospital, Department of Clinical Biochemistry, Skejby, Denmark
| | - Torben F. Orntoft
- Aarhus University Hospital, Department of Clinical Biochemistry, Skejby, Denmark
| | | | - Ellen C. Zwarthoff
- Department of Pathology, Erasmus MC, Rotterdam, The Netherlands
- * E-mail:
| |
Collapse
|
18
|
Methylation markers for urine-based detection of bladder cancer: the next generation of urinary markers for diagnosis and surveillance of bladder cancer. Adv Urol 2012; 2012:503271. [PMID: 22761614 PMCID: PMC3385670 DOI: 10.1155/2012/503271] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2012] [Accepted: 04/16/2012] [Indexed: 12/31/2022] Open
Abstract
Cancer of the urinary bladder is the fifth most common neoplasm in the industrialized countries. Diagnosis and surveillance are dependent on invasive evaluation with cystoscopy and to some degree cytology as an adjunct analysis. Nomuscle invasive bladder cancer is characterized by frequent recurrences after resection, and up to 30% will develop an aggressive phenotype. The journey towards a noninvasive test for diagnosing bladder cancer, in order to replace or extend time between cystoscopy, has been ongoing for more than a decade. However, only a handful of tests that aid in clinical decision making are commercially available. Recent reports of DNA methylation in urine specimens highlight a possible clinical use of this marker type, as high sensitivities and specificities have been shown. This paper will focus on the currently available markers NMP22, ImmunoCyt, and UroVysion as well as novel DNA methylation markers for diagnosis and surveillance of bladder cancer.
Collapse
|
19
|
Hematuria one-stop clinic: first experience in Italy with 150 cases. Urologia 2011; 78:262-6. [PMID: 22139806 DOI: 10.5301/ru.2011.8873] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/28/2011] [Indexed: 11/20/2022]
Abstract
OBJECTIVES Starting from the UK experience, we decided to test both the feasibility and the advantages of this diagnostic pathway now established in an Italian hospital. We analyzed the outcomes in detecting transitional cell carcinoma (TCC) of the bladder, other malignant and non-malignant conditions. MATERIALS AND METHODS Between April and December 2010, one hundred and fifty patients presenting with hematuria were referred to the Hematuria One Stop Clinic (HOSC) at our Institution. Each patient underwent a visit, a Urinary Tract Ultrasound, a Cystoscopy and CT IVP in selected cases (evidence of alterations or lesions of the renal parenchyma, presence of stones of the urinary tract, evidence of doubtful or positive urinary cytology). Where a TCC of the bladder was diagnosed, the patient underwent TUR-BT. In other cases (stones, BPH etc.) the appropriate therapeutic pathway was followed. RESULTS 25.3% of patients with hematuria were found to have a bladder cancer; 21.3% had a urinary stone (2% in the bladder); 1.3% had prostate cancer; 1.3% had a renal cell carcinoma. The mean age was 69.8 yrs. 6% of the patients (23.6% on patients with TCC of the bladder) had a G3 disease. The mean time from admission to the HOSC until the operation day, in case of TCC of the bladder, was 10.61 days. CONCLUSIONS The Italian experience of the One Stop Clinic confirms a high rate of bladder cancer detection. Furthermore, a high rate of non-malignant conditions was detected, stressing the importance of the HOSC not only as a cancer clinic but as a complete general urological clinic. We report a shorter waiting time to operation, especially for bladder TCC G3 patients.
Collapse
|
20
|
Hess J, Tschirdewahn S, Szarvas T, Rossi R, Rübben H, Vom Dorp F. [Urothelial carcinoma of the bladder: evaluation by combined endoscopy and urine cytology: is incontrovertible assessment possible?]. Urologe A 2011; 50:702-5. [PMID: 21465088 DOI: 10.1007/s00120-010-2502-6] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
BACKGROUND Transurethral resection of transitional cell carcinoma of the bladder provides a definitive surgical treatment and supplies tissue for histological evaluation. Superficial low-grade carcinomas with a small risk of progression are treated properly with fulguration alone. To justify fulguration as a definitive treatment of papillary bladder tumours, one must be able to safely distinguish low-grade, noninvasive tumours from those that are high grade and potentially invasive. MATERIAL AND METHODS A total of 160 patients with a transitional cell carcinoma at cystoscopy underwent transurethral resection of the tumour. The macroscopic appearance of the tumour, the aspect with bimanual palpation and the perioperative urine cytology were compared with the histological report. RESULTS In our study we were able to safely distinguish low-grade tumours from high-grade tumours. All noninvasive tumours could be identified visually as such. CONCLUSION Urologists skilled in the evaluation of urine cytology can distinguish low-grade noninvasive tumours of the bladder from high-grade and potentially invasive tumours by means of appearance at cystoscopy and perioperative urine cytology.
Collapse
Affiliation(s)
- J Hess
- Klinik für Urologie, Kinderurologie und Urologische Onkologie, Universitätsklinikum Essen, Hufelandstraße 55, 45122 Essen, Deutschland
| | | | | | | | | | | |
Collapse
|
21
|
Strittmatter F, Buchner A, Karl A, Sommer ML, Straub J, Tilki D, Hennenberg M, Knuechel R, Stief CG, Zaak D, Tritschler S. Individual Learning Curve Reduces the Clinical Value of Urinary Cytology. Clin Genitourin Cancer 2011; 9:22-6. [DOI: 10.1016/j.clgc.2011.05.007] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2011] [Revised: 05/13/2011] [Accepted: 05/13/2011] [Indexed: 01/22/2023]
|
22
|
Schwamborn K, Gaisa NT, Henkel C. Tissue and serum proteomic profiling for diagnostic and prognostic bladder cancer biomarkers. Expert Rev Proteomics 2011; 7:897-906. [PMID: 21142890 DOI: 10.1586/epr.10.82] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
A panel of biomarkers for the early detection of bladder cancer has not yet been identified. Many different molecules, including DNA, RNA or proteins have been reported but none have provided adequate sensitivity for a single-tier screening test or a test to replace cystoscopy. Therefore, multimarker panels are discussed at present to give a more-precise answer to the biomarker quest. Mass spectrometry or 2D gel-electrophoresis have evolved greatly within recent years and are capable of analyzing multiple proteins or peptides in parallel with high sensitivity and specificity. However, transmission of screening results from one laboratory to another is still the main pitfall of those methods; a fact that emphasizes the need for consistent and standardized procedures as suggested by the Human Proteome Organization (HUPO). In this article, recent results in screening approaches and other proteomic techniques used for biomarker evaluation in bladder cancer are discussed with a focus on serum and tissue biomarkers.
Collapse
Affiliation(s)
- Kristina Schwamborn
- Institute of Pathology, RWTH Aachen University, Pauwelsstrasse 30, Aachen, Germany.
| | | | | |
Collapse
|
23
|
Saint F, Quintens H, Roupret M, Amsellem-Ouazana D, Mazerolles C, Wallerand H, Bernardini S, Guy L, Soulié M, Pfister C. [Diagnostic test for bladder cancer: the NMP22®]. Prog Urol 2011; 21:245-9. [PMID: 21482397 DOI: 10.1016/j.purol.2010.09.027] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2010] [Revised: 08/30/2010] [Accepted: 09/04/2010] [Indexed: 10/18/2022]
Abstract
INTRODUCTION Diagnosis and follow-up of bladder cancer is based on cytology and cystoscopic exams. Cytology is highly specific but remains with a highly variable sensitivity. Cystoscopy is an invasive exam and has shown specific limits. Urinary test, highly specific and highly sensitive, might be ideal to replace the couple cytology-cystoscopy. MATERIAL AND METHODS Through a literature review, using MeSH system and Pubmed system (keywords: NMP22 and bladder cancer), authors pointed to the value of NMP22 to replace cystoscopy and cytology. RESULTS Between 1996 and 2010, 193 publications were identified with these keywords. Seventeen original articles have been selected based on their quality and methodology. NMP22 was more sensitive than cytology for follow-up and screening of bladder cancer. As screening test, NMP22 has shown positive predictive value between 0 and 70%. As follow-up test, NMP22 has shown more stable positive predictive value close to 70%. Coupled to cytology, NMP22 has shown predictive positive value up to 90%. CONCLUSION For screening test, NMP22 should be the referent test for best selection cases (tobacco, hematuria) and for systemic elimination of false positive cases (ureteral stent, lithiasis). For follow-up test, NMP22-cytology should be the new reference. Moreover, when NMP22 is positive with negative cystoscopy, follow-up may be carefully proposed (recurrence risk×10).
Collapse
Affiliation(s)
- F Saint
- Service d'urologie-transplantation, CHU Hôpital Sud, avenue R.-Laennec, Salouel, 80054 Amiens cedex 1, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Tritschler S, Sommer ML, Straub J, Hocaoglu Y, Tilki D, Strittmatter F, Zaak D, Stief C, Karl A. Urinary cytology in era of fluorescence endoscopy: redefining the role of an established method with a new reference standard. Urology 2010; 76:677-80. [PMID: 20434197 DOI: 10.1016/j.urology.2010.01.083] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2009] [Revised: 12/25/2009] [Accepted: 01/15/2010] [Indexed: 11/19/2022]
Abstract
OBJECTIVES To assess whether the use of fluorescence endoscopy (FE) decreases the clinical value of urinary cytology compared with the use of white light endoscopy (WLE). METHODS The endoscopic, cytologic, and histologic findings of patients who had undergone transurethral resection of the bladder with or without FE were reviewed. The number and characteristics of the tumors that had been overlooked by WLE or FE but detected by cytology were analyzed. An assessment of whether the sensitivity and specificity of urinary cytology changed according to the use of FE or WLE was conducted. RESULTS The data from 1705 patients were included. Histologic findings were obtained from 238 patients using WLE and from 1467 patients using FE. Histologically confirmed malignancy was found in 641 patients, and the disease of 1064 was classified as benign. FE was superior to WLE in sensitivity in the detection of bladder cancer (94.3% vs 86.3%, P <.05). Cytology detected 53 of 88 tumors that were not detected by WLE (47 high-grade tumors); 31 tumors were overlooked by FE, of which 20 were detected by cytology (12 were high-grade tumors). The sensitivity and specificity of cytology was 66.0% and 78.4%, respectively. The specificity of cytology using WLE and FE was 75% and 79.1% (P >.05) and the sensitivity was 61.4% and 67.4% (P >.05), respectively. CONCLUSIONS Although FE demonstrated a great sensitivity, cytology still has a role even when using FE, because a small group of patients with high-grade tumors were detected by urinary cytology only.
Collapse
|
25
|
Fritsche HM, Burger M, Dietmaier W, Denzinger S, Bach E, Otto W, Doblinger M, Schwarz S, Buchner H, Hartmann A. Multicolor FISH (UroVysion) facilitates follow-up of patients with high-grade urothelial carcinoma of the bladder. Am J Clin Pathol 2010; 134:597-603. [PMID: 20855641 DOI: 10.1309/ajcpkkwbdsaoz4rw] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Abstract
The aim of the present prospective study was to assess the diagnostic benefit of UroVysion (Vysis-Abbott Laboratories, Downers Grove, IL) in the follow-up of patients with a history of high-grade non-muscle-invasive urothelial carcinoma of the bladder (NMIBC). An unselected cohort of 25 patients with a history of high-grade NMIBC was prospectively followed up by office-based cystoscopy, cytology, and UroVysion in 210 events. The sensitivity and specificity for standard combined cystoscopy and cytology were 78% and 83%, respectively. UroVysion yielded a considerably higher detection rate with 94% and 93%, respectively. In 89% of the follow-up events of patients with a history of previous carcinoma in situ (CIS) and negative cystoscopy but a positive UroVysion finding, CIS recurrence was noticed within 5 months. UroVysion is a worthwhile approach in patients with previous CIS, a high risk for the development of CIS, or previous unequivocal cytology suggestive of CIS, especially during or shortly after instillation therapy.
Collapse
|
26
|
Lai Y, Ye J, Chen J, Zhang L, Wasi L, He Z, Zhou L, Li H, Yan Q, Gui Y, Cai Z, Wang X, Guan Z. UPK3A: a promising novel urinary marker for the detection of bladder cancer. Urology 2010; 76:514.e6-11. [PMID: 20346489 DOI: 10.1016/j.urology.2009.11.045] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2009] [Revised: 11/08/2009] [Accepted: 11/21/2009] [Indexed: 02/03/2023]
Abstract
OBJECTIVES Current methods for reliable detection of bladder cancer have some limitations. Finding better noninvasive methods for detection of bladder cancer is an important topic in urology. We want to evaluate prospectively the early detection power of human uroplakin 3 A (UPK3A) for bladder cancer. METHODS Urine samples were obtained from 32 healthy volunteers, 44 patients with benign urological disorders and 122 patients with bladder cancer. The urine UPK3A levels were quantified by enzyme-linked immunosorbent assay. All the samples were also tested with NMP22 test and cytology examination. RESULTS The urinary UPK3A levels are uniformly elevated in bladder cancer patients than in those of normal volunteers and patients with benign urological disorders, and the differences in the mean urinary UPK3A levels of bladder cancer patients and those of normal individuals or benign urological disorders are statistically significant (P <.01). The receiver operating characteristic (ROC) curve of UPK3A showed an excellent area under the ROC curve of 0.907. In this study, the optimal combination of sensitivity and specificity were determined as 83% and 83%, for a cut-off value of absorbance unit 0.0685, respectively. The sensitivity of urine UPK3A, NMP22, and cytology for detecting bladder cancer were 83%, 58%, and 64%, respectively, whereas specificity was 83%, 75%, and 82%, respectively. CONCLUSIONS We conclude that individuals with bladder cancer have higher UPK3A values. Our data suggest that urine measurement of UPK3A is a sensitive marker for the detection of bladder cancer. However, it needs further studies in larger cohorts.
Collapse
Affiliation(s)
- Yongqing Lai
- Department of Urology and Shenzhen Key Laboratory of Male Reproduction and Genetics, Peking University Shenzhen Hospital, PR China
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Tritschler S, Karl A, Sommer ML, Straub J, Strittmatter F, Tilki D, Hocaoglu Y, Stief C, Zaak D. Influence of clinical information on the interpretation of urinary cytology in bladder cancer: how suggestible is a cytologist? BJU Int 2010; 106:1165-8. [DOI: 10.1111/j.1464-410x.2010.09285.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
28
|
Affiliation(s)
- Hugh Mostafid
- Department of Urology, North Hampshire Hospital, Basingstoke, Hampshire, UK.
| | | | | | | |
Collapse
|
29
|
Horstmann M, Patschan O, Hennenlotter J, Senger E, Feil G, Stenzl A. Combinations of urine-based tumour markers in bladder cancer surveillance. ACTA ACUST UNITED AC 2009; 43:461-6. [DOI: 10.3109/00365590903296837] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Affiliation(s)
- Marcus Horstmann
- Department of Urology, Eberhard Karls University Tuebingen, Tuebingen, Germany
| | - Oliver Patschan
- Department of Urology, Eberhard Karls University Tuebingen, Tuebingen, Germany
| | - Jörg Hennenlotter
- Department of Urology, Eberhard Karls University Tuebingen, Tuebingen, Germany
| | - Erika Senger
- Department of Urology, Eberhard Karls University Tuebingen, Tuebingen, Germany
| | - Gerhard Feil
- Department of Urology, Eberhard Karls University Tuebingen, Tuebingen, Germany
| | - Arnulf Stenzl
- Department of Urology, Eberhard Karls University Tuebingen, Tuebingen, Germany
| |
Collapse
|
30
|
Villicana P, Whiting B, Goodison S, Rosser CJ. Urine-based assays for the detection of bladder cancer. Biomark Med 2009; 3:265. [PMID: 20161673 DOI: 10.2217/bmm.09.23] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Bladder cancer is one of the most prevalent cancers worldwide. Furthermore, nonmuscle invasive bladder cancer has a 70% rate of recurrence, making it a considerable strain to the healthcare system. Patients with bladder cancer require repeat cystoscopic examinations of the bladder to monitor for tumor recurrence. The reason these patients have to undergo these costly, painful, invasive procedures is owing to the absence of accurate urine-based assays to detect the presence of bladder cancer noninvasively. Consequently, the development of a urine-based test to detect bladder cancer would be of tremendous benefit to both patients and healthcare systems. This article reports some of the more prominent urine markers in use today. In addition, the article will highlight some new technologies that are used to investigate novel urinary markers.
Collapse
Affiliation(s)
- Patrick Villicana
- Department of Urology, The University of Florida, College of Medicine, Suite N2-3, PO Box 100247, Gainesville, FL 32610, USA
| | | | | | | |
Collapse
|
31
|
Garcia Castro M, Fernández Fernández E, Martín Corriente MC, Garcia Hernández S, Alvarez-Argüelles CH. [Usefulness of urine cytology for bladder carcinoma diagnosis: comparative study with biopsy]. Actas Urol Esp 2009; 32:904-7. [PMID: 19044300 DOI: 10.1016/s0210-4806(08)73958-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
OBJECTIVES Traditionally, urine cytology has been considered as the gold standard for bladder cancer screening. However, new methods are playing new roles in these cases. In order to assess the value of cytology of voided urine we performed one comparative study between cytology and biopsy. METHODS We retrospectively analyzed the results of urine cytology and biopsy follow-up in 109 patients. All cytologies were from voided urine. They were cytocentrifuged and stained with Papanicolaou stain. RESULTS We found 70 true positive cases and 24 true negative cases. Sensitivity was calculated to be 97% and specifity 96-100%. 12 cases had the first cystoscopy test and biopsy negative, as the cancer was diagnosed in the second biopsy. CONCLUSIONS Patients with clearly positive urine cytology, which was not confirmed in a first cystoscopic study, should be carefully followed up to identify a possible bladder or upper urinary tract cancer. The urine cytology still has a significant role as the gold standard for bladder cancer screening.
Collapse
Affiliation(s)
- Ma Garcia Castro
- Sección de Citología Clínica,. Hospital Universitario de Canarias, La Laguna, Tenerife.
| | | | | | | | | |
Collapse
|
32
|
Watson JA, Burling K, Fitzpatrick P, Kay E, Kelly J, Fitzpatrick JM, Dervan PA, McCann A. Urinary insulin-like growth factor 2 identifies the presence of urothelial carcinoma of the bladder. BJU Int 2008; 103:694-7. [PMID: 19040529 DOI: 10.1111/j.1464-410x.2008.08213.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
OBJECTIVE To examine urinary insulin-like growth factor 2 (IGF-2) levels in patient urine samples and determine the potential of IGF-2 as a marker for the presence of urothelial carcinoma of the bladder (UCB). PATIENTS AND METHODS The current gold standard for diagnosis of UCB is cystoscopy and cytological analysis. The identification of an accurate urine marker for UCB with the potential to replace unnecessary cystoscopy would benefit patients with UCB and others investigated after detecting haematuria. In the present study, we analysed 65 urine samples, and optimized an enzyme-linked immunosorbent assay-based approach to measure urinary levels of IGF-2. RESULTS Based on a threshold of 5.4 ng/mL, patients with UCB have significantly elevated levels of urinary IGF-2 (P = 0.009) and this difference remained significant after adjustment for age and sex (P = 0.04). Sensitivity and specificity values of 80% and 52%, respectively, were determined for urinary IGF-2 alone and when combined with nuclear matrix protein 22 (NMP22; an approved biomarker for detection of UCB). There was a positive correlation between urinary IGF-2 levels and NMP22 levels in patient urine samples and the combined assay improved the detection of UCB (sensitivity 85% and specificity 52%). CONCLUSION Substantiated evidence has identified IGF-2 as a valuable marker for UCB. In addition, the novel observations of the present study have shown that aberrant levels of IGF-2 occurring in the presence of UCB, can now be determined through a simple and inexpensive urine assay.
Collapse
Affiliation(s)
- Jenny A Watson
- The UCD School of Medicine and Medical Sciences, University College Dublin, Ireland.
| | | | | | | | | | | | | | | |
Collapse
|
33
|
Lee CS, Yoon CY, Witjes JA. The past, present and future of cystoscopy: the fusion of cystoscopy and novel imaging technology. BJU Int 2008; 102:1228-33. [DOI: 10.1111/j.1464-410x.2008.07964.x] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
34
|
Bott S, Chanawani M, Mostafid H. The Use of the NMP22 BladderChek Test for Bladder Cancer to Optimise Investigations in a One-Stop Haematuria Clinic. ACTA ACUST UNITED AC 2008. [DOI: 10.1016/j.bjmsu.2008.07.006] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Objective: We assessed the value of the NMP22 BladderChek point-of-care (POC) test (Kyowa Hakko UK Ltd., Slough, UK) in a one-stop haematuria clinic to optimise the choice of further investigations. Patients and methods: Over 34 months from 2005 until 2007, 590 patients presenting to a haematuria clinic were initially assessed with the NMP22 POC test. Patients with a positive NMP22 were counselled and offered further investigation with upper tract imaging and a general anaesthetic cystoscopy without first undergoing flexible cystoscopy (FC). The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the NMP22 POC test in this setting were calculated. The financial impact of this policy was assessed. Results: In total 58 of 590 men were NMP22 positive. Urothelial malignancy was identified in 22 patients and 5 had a non-urothelial malignancy of the genitourinary system. The sensitivity of the NMP22 test in detecting urothelial malignancy in newly presenting patients was 56.4%, specificity 93.5%, PPV 38.0% and NPV 97.0%. Eleven had no abnormality and none have subsequently developed a malignancy. The number of patients requiring FC fell by 10% resulting in significant financial savings. Conclusion: The NMP22 POC test can be used as the first test in a haematuria clinic to optimise the choice of subsequent investigations resulting in financial savings.
Collapse
Affiliation(s)
- Simon Bott
- Basingstoke and North Hampshire NHS Foundation Trust, Aldermaston Road, Basingstoke, Hampshire RG24 9NA, United Kingdom
| | - Malek Chanawani
- Basingstoke and North Hampshire NHS Foundation Trust, Aldermaston Road, Basingstoke, Hampshire RG24 9NA, United Kingdom
| | - Hugh Mostafid
- Basingstoke and North Hampshire NHS Foundation Trust, Aldermaston Road, Basingstoke, Hampshire RG24 9NA, United Kingdom
| |
Collapse
|
35
|
Sangar VK, Ramani VA, George NJ. SHOULD MOLECULAR TECHNOLOGY REPLACE URINE CYTOLOGY? BJU Int 2008; 102:1361. [DOI: 10.1111/j.1464-410x.2008.07890.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
36
|
Gromov P, Moreira JMA, Gromova I, Celis JE. Proteomic strategies in bladder cancer: From tissue to fluid and back. Proteomics Clin Appl 2008; 2:974-88. [PMID: 21136898 DOI: 10.1002/prca.200780163] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2007] [Indexed: 12/18/2022]
Abstract
We have applied protein expression profiling technologies in combination with immunohistochemistry, using fresh tissue and urine samples, to assess bladder cancer heterogeneity and prognosis as well as to generate protein markers for tumor progression and early diagnosis of the disease. Here, we review some selected lines of investigation and approaches undertaken by our laboratory, drawing on more than 15 years of experience in bladder cancer proteomics, to highlight a number of issues that may be useful for researchers entering the field. In particular, we address the identification of markers for bladder cancer progression and exemplify the potential of gel-based proteomic profiling of urine samples for the early detection of urothelial carcinomas. In addition, we provide a brief description of a novel and highly promising source of biomarkers, the tumor interstitial fluid (TIF) that perfuses the tumor microenvironment.
Collapse
Affiliation(s)
- Pavel Gromov
- Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark.
| | | | | | | |
Collapse
|
37
|
Vrooman OPJ, Witjes JA. Urinary markers in bladder cancer. Eur Urol 2007; 53:909-16. [PMID: 18162285 DOI: 10.1016/j.eururo.2007.12.006] [Citation(s) in RCA: 134] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2007] [Accepted: 12/04/2007] [Indexed: 12/29/2022]
Abstract
OBJECTIVES Many markers for the detection of bladder cancers have been tested. Almost all urinary markers reported are better than cytology with regard to sensitivity, but they score lower in specificity. The purpose of this review is to highlight the most important urinary biomarkers studied and reported recently. METHODS Literature on bladder cancer markers has been reviewed regularly in the last few years. In the current review we have tried to summarise the most recent literature of urinary markers. RESULTS The results of this review show that the first-generation urinary markers did not add much to urinary cytology. The current generation of markers is promising but larger clinical trails are needed. The future of marker development is bright with new techniques emerging, but the perfect marker is still to be found. CONCLUSION Currently, no single marker can yet guide us in surveillance and lower the frequency of urethrocystoscopy.
Collapse
Affiliation(s)
- Olaf P J Vrooman
- Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
| | | |
Collapse
|